The Business Research Company’s report on the Esketamine Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
How are market drivers shaping the future growth trajectory of the esketamine industry?
The increasing prevalence of treatment-resistant depression (TRD) is expected to propel the growth of the esketamine market in the coming years. Treatment-resistant depression (TRD) refers to depression that doesn’t improve after trying at least two different antidepressant medications at proper doses for a sufficient duration. Treatment-resistant depression (TRD) is increasing due to the limited efficacy of conventional antidepressants, leading to prolonged and recurrent depressive episodes. Esketamine helps treatment-resistant depression (TRD) by providing a fast-acting mechanism that targets the NMDA receptors, offering relief for patients who do not respond to traditional antidepressants. For instance, in September 2023, the National Institute of Mental Health (NIMH), a US-based federal agency, reported that, in 2023, about 30% of individuals with major depressive disorder in the U.S. are resistant to standard treatments. Therefore, the rising incidence of treatment-resistant depression is driving the growth of the esketamine market.
Access Your Free Sample of the Global Esketamine Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=23393&type=smp
What is the estimated market size of the esketamine sector by 2029, based on current forecasts?
The esketamine market size has grown rapidly in recent years. It will grow from $1.37 billion in 2024 to $1.52 billion in 2025 at a compound annual growth rate (CAGR) of 11.2%. The growth in the historic period can be attributed to an increased number of patients, increasing prevalence of mental health issues in the world, improved awareness level of disease state, rising demand for novel therapeutic options, and favorable regulatory approvals.
The esketamine market size is expected to see rapid growth in the next few years. It will grow to $2.31 billion in 2029 at a compound annual growth rate (CAGR) of 11.0%. The growth in the forecast period can be attributed to the increasing prevalence of treatment-resistant depression, increasing investment in research and development programs, demand for smart healthcare infrastructure, the growing trend of telehealth services, and the growing acceptance of esketamine as an effective treatment. Major trends in the forecast period include partnerships between biotech firms and mental health organizations, robotics in healthcare applications, personalized medicine strategies, sensor-based devices, and the potential for combination therapies.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=23393&type=smp
Who are the top players in the esketamine market?
Major companies operating in the esketamine market are Cigna Corporation, Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Sigma-Aldrich Corporation, Horizon Therapeutics plc, Hikma Pharmaceuticals plc, Cerecor Inc., Celon Pharma S.A., Nortec Química S.A., XWPharma Ltd., Seqens Group, SynZeal Research Pvt. Ltd., Arevipharma GmbH, Sage Therapeutics Inc., Supriya Lifescience Ltd., Clexio Biosciences Ltd., Maithri Drugs Pvt. Ltd., VistaGen Therapeutics Inc.
What trends will propel the growth and evolution of the esketamine market?
Major companies operating in the esketamine market are focusing on developing advanced treatment solutions, such as monotherapy, to enhance depressive symptom relief beyond what placebo offers. Monotherapy refers to the use of a single drug or treatment to manage a disease or medical condition, rather than combining multiple therapies. For instance, in January 2025, Johnson & Johnson, a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved SPRAVATO (esketamine) as the first and only monotherapy for adults with treatment-resistant depression (TRD). Supported by clinical trials, the approval demonstrated that SPRAVATO could rapidly alleviate depressive symptoms, with significant improvements observed within 24 hours. This breakthrough provides a critical option for approximately 30% of individuals who do not respond to traditional antidepressants, eliminating the need for concurrent oral medications. While SPRAVATO has a favorable safety profile, it is administered under a Risk Evaluation and Mitigation Strategy (REMS) to address potential side effects. This milestone marks a significant advancement in TRD treatment, offering renewed hope for improved patient outcomes.
Which geography holds the highest esketamine market share?
North America was the largest region in the esketamine market in 2024. The regions covered in the esketamine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/esketamine-global-market-report
How do different segments contribute to the overall expansion of the esketamine market?
The esketamine market covered in this report is segmented –
1) By Type: Oral Medications, Injection, Nasal Spray, Other Types
2) By Indication: Major Depressive Disorder, Chronic Pain, Post-Traumatic Stress Disorder, Anxiety Disorders
3) By Patient Type: Adult Patients, Pediatric Patients, Geriatric Patients
4) By Application: General Anesthetic, Treatment-Resistant Depression
5) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
Subsegments:
1) By Oral Medications: Immediate-Release Tablets, Extended-Release Tablets, Sublingual Tablets
2) By Injection: Intravenous Injection, Intramuscular Injection, Subcutaneous Injection
3) By Nasal Spray: Prescription Nasal Spray, Over-The-Counter Nasal Spray, Combination Therapy Nasal Spray
4) By Other Types: Plasmapheresis, Intravenous Immunoglobulin (IVIG) Therapy, Stem Cell Therapy
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23393
What defines the structure and scope of the esketamine market?
Esketamine refers to a fast-acting anesthetic and antidepressant derived from ketamine, known for its NMDA receptor antagonist properties. It is used for treatment-resistant depression and major depressive disorder with suicidal ideation, administered as a nasal spray under medical supervision.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
